Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Thromboembolism: early-phase trial registry

2 of 10 indexed Thromboembolism trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Thromboembolism: 10 US clinical trials tracked, 2 recruiting.

Thromboembolism is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Utah, running 2 of these trials.

Enrollment posture brief

Registry condition thromboembolism

OPEN 2 | RECR 20% | LATE 1 | EARLY 3 | RANK #1724 | SPON 2

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Thromboembolism (this)20%
Open-enrollment share among volume-matched conditions near Thromboembolism

Thromboembolism lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Thromboembolism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Thromboembolism is recruiting below its size-band peers.

    2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Thromboembolism research.

    University of Utah accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Thromboembolism enrolment sits around 86 participants.

    Median target enrolment is 86 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Thromboembolism research is mostly interventional.

    8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 23Phase 41

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2 394 participants

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

Kristen Ban

NCT06657924

RECRUITING NA 30 participants

In Vivo Detection of Circulating Clots in Patients With Thromboembolism

University of Arkansas

NCT05301348

ACTIVE NOT RECRUITING Phase 4 31 participants

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

Northwell Health

NCT03581877

COMPLETED 1,635 participants

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

Medco Health Solutions

NCT00830570

COMPLETED NA 146 participants

Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery

University of Utah

NCT04305756

COMPLETED 110 participants

Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00253669

COMPLETED NA 86 participants

Patient-Centered Anticoagulation Self-Monitoring in Minority Patients

University of Illinois at Chicago

NCT02776566

COMPLETED Phase 2 64 participants

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

University of Utah

NCT06118957

COMPLETED NA 26 participants

Strategies for Anticoagulation During Venovenous ECMO

Vanderbilt University Medical Center

NCT04997265

COMPLETED Phase 2

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT00014352

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 4 1

Named interventions

Most-linked intervention names on Thromboembolism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Enoxaparin Drug
2 trials
Patient Self-Monitoring vs Anticoagulation Clinic Other
1 trials
Moderate Intensity Anticoagulation Other
1 trials
Low intensity anticoagulation Other
1 trials
estramustine phosphate sodium Drug
1 trials
ketoconazole Drug
1 trials
warfarin Drug
1 trials
management of therapy complications Procedure
1 trials

US sites by state

Facility locations filed on Thromboembolism trials. A trial with sites in several states counts in each.

Utah 2 trials
Ohio 2 trials
New York 2 trials
Tennessee 1 trials
Pennsylvania 1 trials
New Jersey 1 trials
North Carolina 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Thromboembolism page

10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thromboembolism condition card totals 10 registered trials; most-linked intervention Enoxaparin; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.